Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

RPEP-073932023Sims, John R; Zimmer, Jennifer A; Evans, Cynthia D; Lu, Ming; Ardayfio, Paul; Sparks, JonDavid; Wessels, Alette M; Shcherbinin, Sergey; Wang, Hong; Monkul Nery, Emel Serap; Collins, Emily C; Solomon, Paul; Salloway, Stephen; Apostolova, Liana G; Hansson, Oskar; Ritchie, Craig; Brooks, Dawn A; Mintun, Mark; Skovronsky, Daniel M

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

JAMA, 330(6), 512-527

View on PubMed ↗Publisher’s paper ↗

Citation

Sims, John R; Zimmer, Jennifer A; Evans, Cynthia D; Lu, Ming; Ardayfio, Paul; Sparks, JonDavid; Wessels, Alette M; Shcherbinin, Sergey; Wang, Hong; Monkul Nery, Emel Serap; Collins, Emily C; Solomon, Paul; Salloway, Stephen; Apostolova, Liana G; Hansson, Oskar; Ritchie, Craig; Brooks, Dawn A; Mintun, Mark; Skovronsky, Daniel M. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.. JAMA, 330(6), 512-527. https://doi.org/10.1001/jama.2023.13239